TrialEuropean journal of clinical pharmacology2024

Dose selection for aztreonam-avibactam, including adjustments for renal impairment, for Phase IIa and Phase III evaluation.

Shampa Das et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.